{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:19:44Z","timestamp":1790651984327,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["425331\/2016-4"],"award-info":[{"award-number":["425331\/2016-4"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio Grande do Sul","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.msard.2021.103252","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T02:18:13Z","timestamp":1631240293000},"page":"103252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort"],"prefix":"10.1016","volume":"56","author":[{"given":"Renata Barbosa","family":"Paolilo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Albino","family":"da Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira Luisa","family":"Ap\u00f3stolos-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina de Medeiros","family":"Rimkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagoberto","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas Kazutoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2021.103252_bib0001","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/NXI.0000000000000985","article-title":"Pain, depression, and quality of life in neuromyelitis optica spectrum disorder","volume":"8","author":"Ayzenberg","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2021.103252_bib0002","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder. patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103252_bib0003","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1212\/WNL.0000000000002283","article-title":"Clinical features of neuromyelitis optica in children - US Network of pediatric MS centers report","volume":"86","author":"Chitnis","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103252_bib0004","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1212\/WNL.0b013e3181f39a66","article-title":"Long-term follow-up of neuromyelitis optica with a pediatric onset","volume":"75","author":"Collongues","year":"2010","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2021.103252_bib0005","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dmcn.14594","article-title":"Risk factors for academic difficulties in children with myelin oligodendrocyte glycoprotein antibody-associated acute demyelinating syndromes","volume":"62","author":"Deiva","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"issue":"11","key":"10.1016\/j.msard.2021.103252_bib0006","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/dmcn.14629","article-title":"Psychosocial impact of paediatric demyelinating disorders: a scoping review","volume":"62","author":"Duncan","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.msard.2021.103252_bib0007","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.msard.2017.07.014","article-title":"Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community","volume":"17","author":"Eaneff","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103252_bib0008","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.msard.2017.11.002","article-title":"Psychiatric comorbidities and suicidality among patients with neuromyelitis optica spectrum disorders in Argentina","volume":"19","author":"Fernandez","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2021.103252_bib0009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/dmcn.14242","article-title":"Fatigue, depression, and quality of life in children with multiple sclerosis: a comparative study with other demyelinating diseases","volume":"62","author":"Florea","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"issue":"6","key":"10.1016\/j.msard.2021.103252_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-018-0502-9","article-title":"Pediatric neuromyelitis optica spectrum disorders","volume":"20","author":"Gombolay","year":"2018","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.msard.2021.103252_bib0011","doi-asserted-by":"crossref","unstructured":"K.B. Holroyd, G.S. Manzano, M. Levy, 2020. Update on neuromyelitis optica spectrum disorder. Current Opinion in Ophthalmology Publish Ahead of Print.","DOI":"10.1097\/ICU.0000000000000703"},{"key":"10.1016\/j.msard.2021.103252_bib0012","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/WNL.0b013e318229e694","article-title":"Pain in neuromyelitis optica and its effect on quality of life. a cross-sectional study","volume":"77","author":"Kanamori","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103252_bib0013","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2021.103252_bib0014","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7224\/1537-2073.2017-076","article-title":"Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D","volume":"21","author":"Levy","year":"2019","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2021.103252_bib27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.msard.2018.08.023","article-title":"Resilience and depression\/anxiety symptoms in multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"25","author":"Nakazawa","year":"2018","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"5","key":"10.1016\/j.msard.2021.103252_bib0015","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.msard.2021.103252_bib0016","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000837","article-title":"Treatment and outcome of aquaporin-4 antibody\u2013positive NMOSD","volume":"7","author":"Paolilo","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103252_bib0017","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody positive and AQP4 antibody positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103252_bib0018","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.msard.2016.11.008","article-title":"Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders","volume":"11","author":"Schmidt","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2021.103252_bib0019","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/jpepsy\/jsx093","article-title":"Health-related quality of life in pediatric patients with demyelinating diseases: relevance of disability, relapsing presentation, and fatigue","volume":"43","author":"Self","year":"2018","journal-title":"J. Pediatr. Psychol."},{"key":"10.1016\/j.msard.2021.103252_bib0020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jneuroim.2016.02.011","article-title":"Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression","volume":"293","author":"Shi","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2021.103252_bib0021","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1590\/0103-0582201432214313","article-title":"Tools used for evaluation of Brazilian children's quality of life","volume":"32","author":"Souza","year":"2014","journal-title":"Rev. Paul. Pediatr."},{"issue":"4","key":"10.1016\/j.msard.2021.103252_bib0022","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pediatrneurol.2013.12.006","article-title":"Long-term neurocognitive outcome and quality of life in pediatric acute disseminated encephalomyelitis","volume":"50","author":"Suppiej","year":"2014","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.msard.2021.103252_bib0023","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fped.2020.00339","article-title":"Pediatric NMOSD: a review and position statement on approach to work-up and diagnosis","volume":"8","author":"Tenembaum","year":"2020","journal-title":"Front. Pediatr."},{"issue":"8","key":"10.1016\/j.msard.2021.103252_bib0024","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","article-title":"PedsQLTM 4.0: reliability and validity of the pediatric quality of life inventoryTM version 4.0 generic core scales in healthy and patient populations","volume":"39","author":"Varni","year":"2001","journal-title":"Med. Care"},{"key":"10.1016\/j.msard.2021.103252_bib0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"89","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103252_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577093","article-title":"Sexual dysfunction in patients with neuromyelitis optica spectrum disorder","volume":"338","author":"Zhang","year":"2020","journal-title":"J. Neuroimmunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821005198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821005198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:59:21Z","timestamp":1761901161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821005198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":27,"alternative-id":["S2211034821005198"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103252","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103252"}}